GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports (updated)
UPDATE 2-GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports Updates with GE HealthCare declining to comment
Sept 13 (Reuters) - GE HealthCare Technologies GEHC.O is in talks over a possible $1 billion deal to buy radiopharmaceutical developer Sofie Biosciences, the Financial Times reported on Sunday, citing people familiar with the matter.
Here are some details:
A deal for Sofie, which specializes in radioactive chemicals used in cancer scans, could be announced as soon as next week, the report said.
Reuters could not immediately verify the report. GE HealthCare declined to comment while Sofie Biosciences could not be immediately reached for comment outside regular business hours.
The potential deal would be GE HealthCare’s second major acquisition since it broke away as part of U.S. conglomerate General Electric’s GE.N three-way split in 2024.
Acquiring Sofie would help bolster GE HealthCare’s pharmaceutical diagnostics division, which supplies the agents and chemicals used in scans, the report said.
(Reporting by Devika Nair in Bengaluru; Editing by Susan Fenton and David Gregorio)
((Devika.MadhusudhananNair@thomsonreuters.com))
Recent news on GE HealthCare Technologies
See all newsBrief: GE Healthcare Expands General Imaging Ultrasound Portfolio With Logiq Focus
Brief: SA's Competition Commission Refers GE, Siemens, Philips Units To Tribunal For Alleged Anticompetitive Conduct
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
GE HealthCare slip after $945 million deal for Sofie Biosciences